| Inhibition of ABCB1 overcomes cancer stem cell–like properties and acquired resistance to MET inhibitors in non–small cell lung cancer T Sugano, M Seike, R Noro, C Soeno, M Chiba, F Zou, S Nakamichi, ... Molecular cancer therapeutics 14 (11), 2433-2440, 2015 | 67 | 2015 |
| Short Hydration in Chemotherapy Containing Cisplatin (≥75 mg/m2) for Patients with Lung Cancer: A Prospective Study H Horinouchi, K Kubota, H Itani, TK Taniyama, S Nakamichi, H Wakui, ... Japanese journal of clinical oncology 43 (11), 1105-1109, 2013 | 67 | 2013 |
| Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non–small-cell lung … S Yagishita, H Horinouchi, TK Taniyama, S Nakamichi, S Kitazono, ... International Journal of Radiation Oncology* Biology* Physics 91 (1), 140-148, 2015 | 54 | 2015 |
| A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors S Nakamichi, H Nokihara, N Yamamoto, Y Yamada, K Honda, Y Tamura, ... Cancer Chemotherapy and Pharmacology 76, 1153-1161, 2015 | 49 | 2015 |
| Ankyrin repeat domain 1 overexpression is associated with common resistance to afatinib and osimertinib in EGFR-mutant lung cancer A Takahashi, M Seike, M Chiba, S Takahashi, S Nakamichi, M Matsumoto, ... Scientific reports 8 (1), 14896, 2018 | 46 | 2018 |
| Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors H Wakui, N Yamamoto, S Nakamichi, Y Tamura, H Nokihara, Y Yamada, ... Cancer chemotherapy and pharmacology 73, 511-516, 2014 | 44 | 2014 |
| A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors H Wakui, N Yamamoto, S Kitazono, H Mizugaki, S Nakamichi, Y Fujiwara, ... Cancer chemotherapy and pharmacology 74, 15-23, 2014 | 43 | 2014 |
| Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer S Nakamichi, M Seike, A Miyanaga, M Chiba, F Zou, A Takahashi, ... Oncotarget 9 (43), 27242, 2018 | 41 | 2018 |
| Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling S Takahashi, R Noro, M Seike, C Zeng, M Matsumoto, A Yoshikawa, ... International journal of molecular sciences 22 (8), 4005, 2021 | 28 | 2021 |
| A phase I study of resminostat in Japanese patients with advanced solid tumors S Kitazono, Y Fujiwara, S Nakamichi, H Mizugaki, H Nokihara, ... Cancer Chemotherapy and Pharmacology 75, 1155-1161, 2015 | 24 | 2015 |
| Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors H Nokihara, Y Yamada, Y Fujiwara, N Yamamoto, H Wakui, S Nakamichi, ... Investigational new drugs 34, 66-74, 2016 | 23 | 2016 |
| Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease S Nakamichi, K Kubota, H Horinouchi, S Kanda, Y Fujiwara, H Nokihara, ... Japanese Journal of Clinical Oncology 43 (4), 422-425, 2013 | 22 | 2013 |
| Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non–small-cell Lung Cancer Developing After Surgery S Nakamichi, H Horinouchi, T Asao, Y Goto, S Kanda, Y Fujiwara, ... Clinical Lung Cancer 18 (6), e441-e448, 2017 | 20 | 2017 |
| IASLC thoracic oncology E-book H Pass, D Ball, G Scagliotti Elsevier Health Sciences, 2017 | 20 | 2017 |
| Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer M Nishio, A Horiike, H Nokihara, H Horinouchi, S Nakamichi, H Wakui, ... Investigational new drugs 33, 632-640, 2015 | 16 | 2015 |
| Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial H Horinouchi, K Kubota, A Miyanaga, S Nakamichi, M Seike, A Gemma, ... ESMO open 3 (1), e000288, 2018 | 12 | 2018 |
| RT-PCR for detecting ALK translocations in cytology samples from lung cancer patients S Nakamichi, M Seike, A Miyanaga, M Chiba, K Matsuda, K Kobayashi, ... Anticancer Research 37 (6), 3295-3299, 2017 | 11 | 2017 |
| A phase 1 study of cabozantinib in japanese patients with advanced solid tumors: anti-tumor activity in NSCLC and GIST H Nokihara, N Yamamoto, S Nakamichi, H Wakui, Y Yamada, L Nguyen, ... Annals of Oncology 24, ix48, 2013 | 11 | 2013 |
| Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report A Fukuizumi, A Miyanaga, M Seike, Y Kato, S Nakamichi, K Chubachi, ... BMC Research Notes 8, 1-5, 2015 | 10 | 2015 |
| A case of an asthma patient receiving omalizumab during pregnancy J Hirashima, M Hojo, M Iikura, Y Hiraishi, S Nakamichi, H Sugiyama, ... Arerugi=[Allergy] 61 (11), 1683-1687, 2012 | 10 | 2012 |
